Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Moderna's Earnings Collapsed. Time to Sell?


When it rains, it pours. Instead of a slow slide, COVID-19 vaccine sales at Moderna (NASDAQ: MRNA) collapsed in the third quarter. 

Investors who were hoping for steady cash flows from this vaccine maker were deeply disappointed when it reported results on Thursday, Nov. 3, 2022. Is it time to cut and run, or are there better days ahead? Here's what you should know.

Moderna has been plowing COVID-vaccine profits into its development pipeline. This could set the company up with new revenue streams, but for now, this is still a one-product business. 

Continue reading


Source Fool.com

Like: 0
Share

Comments